IL254528B - Fused tricyclic derivatives of 1-(cyclo)alkylpyridine-2-one are useful for cancer treatment - Google Patents

Fused tricyclic derivatives of 1-(cyclo)alkylpyridine-2-one are useful for cancer treatment

Info

Publication number
IL254528B
IL254528B IL254528A IL25452817A IL254528B IL 254528 B IL254528 B IL 254528B IL 254528 A IL254528 A IL 254528A IL 25452817 A IL25452817 A IL 25452817A IL 254528 B IL254528 B IL 254528B
Authority
IL
Israel
Prior art keywords
cyclo
cancer
useful
treatment
tricyclic fused
Prior art date
Application number
IL254528A
Other languages
English (en)
Hebrew (he)
Other versions
IL254528A0 (en
Original Assignee
Jubilant Biosys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Biosys Ltd filed Critical Jubilant Biosys Ltd
Publication of IL254528A0 publication Critical patent/IL254528A0/en
Publication of IL254528B publication Critical patent/IL254528B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL254528A 2015-03-30 2017-09-17 Fused tricyclic derivatives of 1-(cyclo)alkylpyridine-2-one are useful for cancer treatment IL254528B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1636CH2015 2015-03-30
PCT/IN2016/050098 WO2016157221A1 (en) 2015-03-30 2016-03-30 Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer

Publications (2)

Publication Number Publication Date
IL254528A0 IL254528A0 (en) 2017-11-30
IL254528B true IL254528B (en) 2020-11-30

Family

ID=56015058

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254528A IL254528B (en) 2015-03-30 2017-09-17 Fused tricyclic derivatives of 1-(cyclo)alkylpyridine-2-one are useful for cancer treatment

Country Status (16)

Country Link
US (2) US10689390B2 (enExample)
EP (1) EP3277683B1 (enExample)
JP (1) JP6764877B2 (enExample)
KR (1) KR102588109B1 (enExample)
CN (1) CN107548393B (enExample)
AU (1) AU2016242473B2 (enExample)
BR (1) BR112017020739B1 (enExample)
CA (1) CA2980266C (enExample)
DK (1) DK3277683T3 (enExample)
ES (1) ES2911886T3 (enExample)
IL (1) IL254528B (enExample)
MX (1) MX376112B (enExample)
PL (1) PL3277683T3 (enExample)
PT (1) PT3277683T (enExample)
RU (1) RU2721120C2 (enExample)
WO (1) WO2016157221A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61803B1 (sr) * 2015-09-09 2021-06-30 Jubilant Biosys Ltd Triciklični fuzioni piridin-2-on derivati i njihova upotreba kao inhibitora brd4
RU2019117356A (ru) * 2016-11-10 2020-12-10 Лосинь Фармасьютикал (Шанхай) Ко., Лтд. Азотсодержащее макроциклическое соединение, способ его получения, фармацевтическая композиция и применение
CN111819181A (zh) * 2018-05-10 2020-10-23 罗欣药业(上海)有限公司 苯并七元杂环类化合物、其制备方法、药物组合物及应用
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
US12527741B2 (en) 2021-06-17 2026-01-20 Wisconsin Alumni Research Foundation Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1545767A (en) * 1976-06-30 1979-05-16 Aspro Nicholas Ltd Isoquinoline derivatives
WO2008133288A1 (ja) 2007-04-25 2008-11-06 Daiichi Sankyo Company, Limited 三環性アリール化合物
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
EP2585465B1 (en) 2010-06-22 2014-11-12 GlaxoSmithKline LLC Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CA2901352A1 (en) * 2013-02-19 2014-08-28 Bayer Pharma Aktiengesellschaft Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines
BR112015022391B1 (pt) * 2013-03-12 2021-12-21 Abbvie Inc Compostos inibidores do domínio bromo tetracíclico, composição farmacêutica que compreende os referidos compostos e usos terapêuticos dos mesmos
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
US9814728B2 (en) * 2013-09-20 2017-11-14 Saint Louis University Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)

Also Published As

Publication number Publication date
RU2017135205A3 (enExample) 2019-07-17
KR20170132278A (ko) 2017-12-01
IL254528A0 (en) 2017-11-30
CA2980266C (en) 2025-05-06
US20180282345A1 (en) 2018-10-04
RU2017135205A (ru) 2019-04-10
AU2016242473A1 (en) 2017-10-26
US20200331926A1 (en) 2020-10-22
MX2017012387A (es) 2018-06-11
AU2016242473B2 (en) 2020-06-25
KR102588109B1 (ko) 2023-10-12
MX376112B (es) 2025-03-07
JP2018510203A (ja) 2018-04-12
US11319326B2 (en) 2022-05-03
HK1248686A1 (zh) 2018-10-19
DK3277683T3 (en) 2022-05-02
CN107548393A (zh) 2018-01-05
EP3277683B1 (en) 2022-03-09
ES2911886T3 (es) 2022-05-23
EP3277683A1 (en) 2018-02-07
CN107548393B (zh) 2021-03-02
US10689390B2 (en) 2020-06-23
NZ735972A (en) 2024-08-30
JP6764877B2 (ja) 2020-10-07
BR112017020739A2 (pt) 2018-07-17
PT3277683T (pt) 2022-06-28
PL3277683T3 (pl) 2022-05-23
CA2980266A1 (en) 2016-10-06
BR112017020739B1 (pt) 2023-03-14
WO2016157221A1 (en) 2016-10-06
RU2721120C2 (ru) 2020-05-15

Similar Documents

Publication Publication Date Title
IL268737A (en) Processes for the preparation of benzodiapine derivatives
IL258154A (en) Pyrazolopyrimidine history as btk inhibitors for cancer treatment
IL246140B (en) History of bicyclic heterocyclics as bromodomain repressors
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
HUE041751T2 (hu) Rákfajták kezeléséhez felhasználható fuzionált biciklusos (hetero)aromás vegyületek
IL286788A (en) Methods for the preparation of cytotoxic benzodiazepine compounds
SMT202100551T1 (it) Derivati di sobetirome
HUE050567T2 (hu) Triciklusos heterociklusok rák kezelésére
EP3135674A4 (en) Novel bicyclic or tricyclic heterocyclic compound
IL254528A0 (en) Condensed tricyclic derivatives of 1-(cyclo)alkylpyridin-2-one are useful for the treatment of cancer
ZA201606921B (en) Use of xanthophylls for the treatment of cancers
EP3164403B8 (en) Tricyclic triazolic compounds
IL267305A (en) Process for the manufacture of diazepine derivatives
SI3221297T1 (sl) Postopek za sintezo benzazepinskih derivatov

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed